B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

DNMT1

MOLECULAR TARGET

DNA methyltransferase 1

UniProt: P26358NCBI Gene: 178613 compounds

DNMT1 (DNA methyltransferase 1) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting DNMT1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1s adenosylhomocysteine2.4811
2egcg0.691
3Oleic Acid0.691
4Anthralin0.691
5Azacitidine0.691
6Azacitidine0.691
7Carboxin0.691
8Cefdinir0.691
9Cefixime0.691
10Decitabine0.691
11Fluorometholone0.691
12Oxytetracycline0.691
13Uridine0.691

About DNMT1 as a Drug Target

DNMT1 (DNA methyltransferase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented DNMT1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

DNMT1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.